Regenxbio (NASDAQ:RGNX) PT Set at $150.00 by Chardan Capital

Chardan Capital set a $150.00 target price on Regenxbio (NASDAQ:RGNX) in a report published on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on RGNX. Svb Leerink upgraded shares of Regenxbio from an underperform rating to a market perform rating and cut their price target for the stock from $38.00 to $37.00 in a research note on Tuesday. ValuEngine upgraded shares of Regenxbio from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Raymond James began coverage on shares of Regenxbio in a research note on Thursday, June 13th. They set an outperform rating for the company. TheStreet cut shares of Regenxbio from a c rating to a d+ rating in a research note on Thursday, May 9th. Finally, Leerink Swann upgraded shares of Regenxbio from an underperform rating to a market perform rating in a research note on Tuesday. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $79.56.

RGNX traded up $0.53 during midday trading on Wednesday, reaching $35.60. 21,923 shares of the company’s stock were exchanged, compared to its average volume of 613,360. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 14.96 and a beta of 0.71. The company has a quick ratio of 14.58, a current ratio of 14.58 and a debt-to-equity ratio of 0.01. Regenxbio has a one year low of $35.00 and a one year high of $83.45. The business has a 50-day simple moving average of $43.98 and a two-hundred day simple moving average of $49.14.



Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.46. The firm had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $5.45 million. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The company’s revenue for the quarter was down 80.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.30 earnings per share. As a group, research analysts anticipate that Regenxbio will post -2.85 EPS for the current fiscal year.

In related news, insider Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $52.54, for a total value of $788,100.00. Following the transaction, the insider now owns 261,000 shares in the company, valued at approximately $13,712,940. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total transaction of $264,950.00. Following the completion of the transaction, the senior vice president now owns 8,006 shares in the company, valued at approximately $424,237.94. The disclosure for this sale can be found here. Insiders sold 73,000 shares of company stock valued at $3,508,800 in the last quarter. 13.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund grew its stake in Regenxbio by 1.8% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,660 shares of the biotechnology company’s stock valued at $668,000 after buying an additional 211 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in Regenxbio by 9.5% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,594 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 225 shares during the last quarter. Mckinley Capital Management LLC Delaware grew its stake in Regenxbio by 51.8% in the 1st quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 303 shares during the last quarter. Berman Capital Advisors LLC grew its stake in Regenxbio by 41.6% in the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 333 shares during the last quarter. Finally, Mason Street Advisors LLC grew its stake in Regenxbio by 5.1% in the 1st quarter. Mason Street Advisors LLC now owns 9,825 shares of the biotechnology company’s stock valued at $563,000 after buying an additional 476 shares during the last quarter. Institutional investors and hedge funds own 81.07% of the company’s stock.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: Do equity income investments outperform growth and income investments?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.